Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lesogaberan (AZD-3355) napadisylate is a potent and selective agonist of GABA B receptors, with an EC 50 of 8.6 nM for human recombinant GABA B receptors. It demonstrates an affinity (Ki) of 5.1 nM for rat GABA B receptors and 1.4 μM for GABA A receptors, as determined by its displacement of [3H]GABA binding in brain membranes. Notably, Lesogaberan napadisylate exerts a peripheral mode of action, inhibiting transient lower esophageal sphincter relaxation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 970.00 |
Description | Lesogaberan (AZD-3355) napadisylate is a potent and selective agonist of GABA B receptors, with an EC 50 of 8.6 nM for human recombinant GABA B receptors. It demonstrates an affinity (Ki) of 5.1 nM for rat GABA B receptors and 1.4 μM for GABA A receptors, as determined by its displacement of [3H]GABA binding in brain membranes. Notably, Lesogaberan napadisylate exerts a peripheral mode of action, inhibiting transient lower esophageal sphincter relaxation. |
Targets&IC50 | GABAA (rat):1.4±0.3 μM (Ki), GABAB (rat):5.1±1.2 nM (Ki), GABAB receptor (human):8.6±0.77 nM (EC50) |
In vitro | Lesogaberan at concentrations of 3-30 nM effectively promotes the proliferation of human islet cells in vitro[2]. Specifically, treatment with Lesogaberan at 3 nM resulted in a marginal, yet statistically insignificant, proliferative effect. Conversely, higher concentrations (10 and 30 nM) significantly enhanced cell proliferation by 2-3 times compared to islets grown in the absence of the compound, as observed over a 4-day incubation period[2]. |
In vivo | Lesogaberan (AZD3355) effectively stimulates human GABA B receptors and reduces transient lower esophageal sphincter relaxation (TLESR) in canine models, demonstrating a biphasic dose-response relationship. Additionally, oral administration of Lesogaberan (0.08 mg/mL for 48 hours) has been shown to protect human islet β-cells from apoptosis in mouse islet grafts. The compound exhibits high oral bioavailability (88% in dogs and 100% in rats) and low systemic clearance in female Sprague Dawley rats, with only 1% plasma protein binding observed in both rat and human plasma. Experimental results include significant reduction in apoptotic cells and increase in insulin-positive β-cells within human islet grafts in diabetic NOD/scid mice following oral administration. |
Synonyms | AZD-3355 napadisylate |
Molecular Weight | 349.31 |
Formula | C13H17FNO5PS |
CAS No. | 477956-38-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lesogaberan napadisylate 477956-38-0 AZD-3355 napadisylate inhibitor inhibit